Inflammation And Pain Post Cataract Surgery Pipeline Insight

DelveInsight’s, “Inflammation and Pain Post Cataract Surgery - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Inflammation and Pain Post Cataract Surgery pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Inflammation and Pain Post Cataract Surgery Understanding

Inflammation and Pain Post Cataract Surgery: Overview

A cataract is a dense cloudy area that forms in the lens of the eye. The problem is common in older people. It is the most common cause of vision loss in developed and developing countries. Cataract surgery is the most commonly performed surgical procedure. The minimally invasive cataract surgery technique with phacoemulsification is considered to be a minor procedure with less complications. However, post-operative problems such as ocular pain and inflammation can cause some problems. Despite surgical advances, post-cataract surgery inflammation is still a common cause of patient discomfort, delayed recovery and reduced visual outcome.


"Inflammation and Pain Post Cataract Surgery - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammation and Pain Post Cataract Surgery pipeline landscape is provided which includes the disease overview and Inflammation and Pain Post Cataract Surgery treatment guidelines. The assessment part of the report embraces, in depth Inflammation and Pain Post Cataract Surgery commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammation and Pain Post Cataract Surgery collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Inflammation and Pain Post Cataract Surgery R&D. The therapies under development are focused on novel approaches to treat/improve Inflammation and Pain Post Cataract Surgery.

Inflammation and Pain Post Cataract Surgery Emerging Drugs Chapters

This segment of the Inflammation and Pain Post Cataract Surgery report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Inflammation and Pain Post Cataract Surgery Emerging Drugs


XG-102: Xigen

XG 102 (AM-111; D-JNKI-1) is an antiapoptotic, protease-resistant peptide that selectively blocks JNK mitogen activated protein kinase inhibitors, which are signalling proteins that transmit extracellular signals from the cell membrane to nuclear and cytoplasmic targets. JNK activation is implicated in autoimmune and inflammatory diseases. The active substance of XG 102, D-JNKI-1, is a peptide that selectively blocks the access of JNK to its substrates within the cell’s nucleus by a mechanism of competitive binding. It is intended to treat post-cataract surgery inflammation and pain. XG 102 is administered as a single subconjunctival injection. It is in phase III clinical trials for post-cataract surgery inflammation and pain.


APP13007: Formosa Pharmaceuticals

APP13007 is an aqueous based ophthalmic nanosuspension positioned for the treatment of post-operative pain and inflammatory eye conditions. The active ingredient in APP13007 is a potent corticosteroid agent whose efficacy and safety for dermatological use has been well established more than 30 years in US, Europe, and Japan. It is nearing completion of phase 2 studies in the United States.


OCS-01: Oculis Pharma

OCS-01 is a novel formulation of dexamethasone using Oculis proprietary Solubilizing Nanoparticle (SNP) technology that enables formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues. It has completed phase 2 clinical trials for treating inflammation and pain following cataract surgery.


SURF-201: Surface Pharmaceuticals

It would be the first betamethasone-based offering for ophthalmic use in the US market. Extremely potent concentration of betamethasone (0.2%) and first unit dose, preservative-free corticosteroid. Surface Pharmaceuticals completes a phase II trial in Ocular Inflammation and Ocular Pain in USA

Further product details are provided in the report……..

Inflammation and Pain Post Cataract Surgery: Therapeutic Assessment

This segment of the report provides insights about the different Inflammation and Pain Post Cataract Surgery drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Inflammation and Pain Post Cataract Surgery

There are approx. 5+ key companies which are developing the therapies for Inflammation and Pain Post Cataract Surgery. The companies which have their Inflammation and Pain Post Cataract Surgery drug candidates in the mid to advanced stage, i.e. phase III include, Xigen and others.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late-stage products (phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Inflammation and Pain Post Cataract Surgery pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Topical
  • Oral
  • Intramuscular
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inflammation and Pain Post Cataract Surgery: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammation and Pain Post Cataract Surgery therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammation and Pain Post Cataract Surgery drugs.

Inflammation and Pain Post Cataract Surgery Report Insights

  • Inflammation and Pain Post Cataract Surgery Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Inflammation and Pain Post Cataract Surgery Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Inflammation and Pain Post Cataract Surgery drugs?
  • How many Inflammation and Pain Post Cataract Surgery drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammation and Pain Post Cataract Surgery?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Inflammation and Pain Post Cataract Surgery therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Inflammation and Pain Post Cataract Surgery and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Inflammation and Pain Post Cataract Surgery: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Inflammation and Pain Post Cataract Surgery – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Inflammation and Pain Post Cataract Surgery companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Inflammation and Pain Post Cataract Surgery Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

XG-102: Xigen

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

APP13007: Formosa Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Inflammation and Pain Post Cataract Surgery Key Companies

Inflammation and Pain Post Cataract Surgery Key Products

Inflammation and Pain Post Cataract Surgery- Unmet Needs

Inflammation and Pain Post Cataract Surgery- Market Drivers and Barriers

Inflammation and Pain Post Cataract Surgery- Future Perspectives and Conclusion

Inflammation and Pain Post Cataract Surgery Analyst Views

Inflammation and Pain Post Cataract Surgery Key Companies

Appendix

List of Table

Table 1: Total Products for Inflammation and Pain Post Cataract Surgery

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Inflammation and Pain Post Cataract Surgery

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Xigen

• Formosa Pharmaceuuticals

• Oculis Pharma

• Surface Pharmaceuticals

  • Tags:
  • "Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...
  • Inflammation and Pain Post Catarac...

Forward to Friend

Need A Quote